Current Headlines

  1. Horizon Therapeutics plc Announces U.S. FDA Acceptance Of Its New Drug Application To Make PROCYSBI (Cysteamine Bitartrate) Available As Oral Granules In Packets
    7/18/2019

    Horizon Therapeutics plc announced recently that the U.S. Food and Drug Administration (FDA) has accepted Horizon’s New Drug Application (NDA) for PROCYSBI (Cysteamine Bitartrate) Delayed-Release Oral Granules in Packets

  2. New Technology Targets Cancer, Other Diseases, And Hidden Elements That Allow Those Diseases To Thrive
    7/18/2019

    A Purdue University-affiliated startup has created a platform aimed at treating relapse patients for cancers and other diseases by taking a holistic approach of not only seeking to impede the main cause but also to stop other elements that help that disease thrive

  3. GigaGen Announces Issuance Of US Patent For Functional Analysis Methods In The Discovery And Development Of Therapeutic Antibodies
    7/18/2019

    GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the United States Patent and Trademark Office has issued U.S. Patent No. 10,329,557, covering methods that enable parallel functional analysis of single cells, a core capability of the company's Surge™ technology

  4. Clarivate Analytics Introduces Cortellis Content-As-A-Service (CaaS) To Accelerate Drug Discovery And Development
    7/18/2019

    Clarivate Analytics plc (NYSE:CCC; CCC.WS), a global leader in providing trusted insights and analytics to accelerate the pace of innovation, today launched an expansion to its Cortellis suite of life science intelligence solutions with programmatic access to scientific data typically used in drug discovery and early stage development

  5. Targeted Protein Degradation For Drug Discovery
    7/18/2019

    AMSBIO has introduced a new range of homogeneous proximity assays, critical enzymes and small molecule inhibitors to assess the chemical adaptor function of Proteolysis Targeting Chimeras (PROTACs)

  6. InSphero Launches Industry's First Automation-Compatible 3D Human Liver Disease Platform For NASH Drug Discovery And Screening
    7/17/2019

    InSphero AG today announced a breakthrough in 3D cell technology for drug discovery and safety testing with the launch of its 3D InSight™ Human Liver Disease Discovery Platform for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)

  7. Gotham Therapeutics And Mercachem Announce Progress In Compound Library Development Tailored For Epitranscriptomic Drug Discovery
    7/17/2019

    Gotham Therapeutics , a biotechnology company developing a novel drug class targeting RNA-modifying proteins, and Mercachem, the leading European contract research organization, recently announced the generation of a high-quality compound library tailor-made for accelerated hit generation and hit-to-lead expansion against large parts of the epitranscriptomic target space

  8. Seelos Therapeutics Announces Investigational New Drug Application Submission For SLS-005
    7/17/2019

    Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase IIb/III clinical study of SLS-005 (trehalose) for the treatment of Sanfilippo syndrome (SFS)

  9. Arrowhead Pharmaceuticals Receives Orphan Drug Designation For ARO-ANG3
    7/16/2019

    Arrowhead Pharmaceuticals Inc. recently announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ARO-ANG3 for the treatment of homozygous familial hypercholesterolemia (HoFH)

  10. Sosei Heptares Enters Into Multi-Target Research Collaboration And License Agreement With Genentech
    7/16/2019

    Sosei Group Corporation ("the Company") (TSE: 4565) announces that it has entered into a multi-target research collaboration and license agreement with Genentech, a member of the Roche Group, to discover and develop novel medicines (new small molecules and/or biologics) that modulate G protein-coupled receptor (GPCR) targets of interest to Genentech